⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 15, 2024Case Reports in OncologyOpen Access

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports

Christian D. Muller Sabine Franke Timo Reisländer Verena Keitel Marino Venerito

View Full Paper

Ask AI

Bookmark

Share

Abstract

Patients with progressing intrahepatic cholangiocarcinoma (iCCA) harboring an isocitrate dehydrogenase 1 (IDH1) mutation who received ivosidenib showed a median progression-free survival (PFS) benefit of 1.3 months compared to placebo in the phase 3 ClarIDHy trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Muller et al. (2024) studied this question.

synapsesocial.com/papers/68e6046bb6db643587597b7e https://doi.org/10.1159/000539665

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinomaSystematic Review · 2026
2Safety and efficacy of ivosidenib in the treatment of isocitrate dehydrogenase 1 mutant cholangiocarcinoma and acute myeloid leukemia: a systematic review and meta-analysis2025
3Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study2025 · 4 citations
4A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.2024 · 7 citations
5Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial2025 · 2 citations

More related papers

Targeting IDH1: Long-Term Efficacy and Tolerance of Ivosidenib in Advanced Chondrosarcoma2026
Ivosidenib in Predominantly Recurrent IDH1-mutant glioma: A Single Institution Experience2026
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response2025

More from Case Reports in Oncology

A Case Report of Suspected Bleeding Disorder of Unknown Cause and Review of Diagnostic Challenges in Unexplained Bleeding after Trans-Urethral Resection of Bladder TumorTue,
Successful reintroduction of alectinib after acute kidney injury due to tubular toxicity in stage IV non-small cell lung cancer: a case reportMon,